[Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome].
Nemchenko
I S
IS
Khoroshko
N D
ND
Turkina
A G
AG
Vinogradova
O Iu
OIu
Sokolova
M A
MA
Abakumov
E M
EM
Semenova
E A
EA
Zakharova
A V
AV
Domracheva
E V
EV
D000328:Adult; D001549:Benzamides; D004804:Eosinophils / Q000187:drug effects; D016044:Fusion Proteins, bcr-abl / Q000032:analysis*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
Glivek v terapii nekotorykh form Ph'- i bcr/abl-negativnykh mieloproliferativnykh zabolevaniĭ i mieloproliferativnogo varianta idiopaticheskogo giperéozinofil'nogo sindroma.